Effect of preoperative radiotherapy for rectal cancer on spermatogenesis.

Br J Surg

Department of Molecular Medicine and Surgery, Karolinska Institutet and Department of Pelvic Cancer, GI Oncology and Colorectal Surgery Unit, Karolinska University Hospital, Stockholm, Sweden.

Published: July 2021

Download full-text PDF

Source
http://dx.doi.org/10.1093/bjs/znab019DOI Listing

Publication Analysis

Top Keywords

preoperative radiotherapy
4
radiotherapy rectal
4
rectal cancer
4
cancer on spermatogenesis
4
preoperative
1
rectal
1
cancer
1
on spermatogenesis
1

Similar Publications

Frequency and treatment outcomes of chest wall masses: a 10-year report.

Kardiochir Torakochirurgia Pol

December 2024

Endoscopic and Minimally Invasive Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Introduction: Chest wall tumors, though rare, represent a significant subset of thoracic neoplasms, accounting for approximately 5% of thoracic and 2% of overall body neoplasms. Their management has historically posed challenges for surgeons, often leading to misdiagnosis, incomplete resection, and high complication rates. An individualized surgical approach, tailored to the specific characteristics of the disease, is crucial for optimizing outcomes.

View Article and Find Full Text PDF

The efficacy of preoperative radiotherapy combined with surgery (preRT + S) for primary retroperitoneal sarcoma (RPS) remains unclear. This study aimed to compare preRT + S with surgery alone (SA) in patients with RPS. Core databases were searched for directly comparative studies depending on preRT.

View Article and Find Full Text PDF

The Role of [F]F-FDG PET/CT for Predicting Histology and Prognosis in Patients with Thymic Lesions.

Mol Diagn Ther

January 2025

Thoracic Surgery and Lung Transplantation, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122, Milan, Italy.

Objectives: To investigate whether 18F-fluorodeoxyglucose positron emission tomography-computed tomography ([F]F-FDG PET/CT) metabolic parameters were associated with histology and to assess their prognostic role in patients with thymic lesions.

Patients And Methods: In total, 116 patients (49/67 M/F; mean age 59.5 years) who underwent preoperative [F]F-FDG PET/CT and thymectomy from 2012 to 2022 were retrospectively analyzed.

View Article and Find Full Text PDF

Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter TONO Study.

Ann Surg Oncol

January 2025

Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Pôle des Pathologies Digestives et Hépatiques, Hôpital de Hautepierre-Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France.

Background: The use of multiagent FOLFIRINOX chemotherapy for pancreatic adenocarcinoma in a neoadjuvant setting has been associated with an increased rate of complete pathological response (CPR) after surgery. This study investigated the long-term outcomes of patients with CPR in a multicenter setting to identify prognostic factors for overall survival (OS) and recurrence-free survival (RFS).

Methods: This retrospective cohort study examined biopsy-proven pancreatic adenocarcinomas with CPR after neoadjuvant chemotherapy or chemoradiotherapy and surgery, between January 2006 and December 2023 across 22 French and  2 Belgian centers.

View Article and Find Full Text PDF

Objective: Ependymomas, rare neuroglial tumors originating from ependymal cells, can occur in the CNS and typically affect the brain's ventricles or spinal cord. Prognosis is influenced by tumor grade, location, resection extent, and preoperative Karnofsky Performance Status Scale (KPSS) scores. This study evaluates clinical features, treatment outcomes, and factors affecting prognosis in patients with intracranial ependymomas.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!